Single Patient Treatment Protocol of TRC105 Combined With Standard-dose Bevacizumab for a Single Patient With Metastatic And Refractory Choriocarcinoma

Trial Profile

Single Patient Treatment Protocol of TRC105 Combined With Standard-dose Bevacizumab for a Single Patient With Metastatic And Refractory Choriocarcinoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 22 May 2017

At a glance

  • Drugs Carotuximab (Primary) ; Bevacizumab
  • Indications Choriocarcinoma
  • Focus Therapeutic Use
  • Sponsors TRACON Pharmaceuticals
  • Most Recent Events

    • 16 May 2017 Planned End Date changed from 1 Mar 2016 to 1 Nov 2017.
    • 16 May 2017 Status changed from recruiting to active, no longer recruiting.
    • 21 Mar 2016 Updated data presented at the Annual Meeting of the Society of Gynecologic Oncology 2016, according to a TRACON Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top